25.82
-0.21 (-0.81%)
| Previous Close | 26.03 |
| Open | 26.16 |
| Volume | 1,815,950 |
| Avg. Volume (3M) | 1,721,159 |
| Market Cap | 15,851,170,816 |
| Price / Earnings (TTM) | 16.77 |
| Price / Earnings (Forward) | 15.13 |
| Price / Sales | 4.23 |
| Price / Book | 2.64 |
| 52 Weeks Range | |
| Earnings Date | 7 May 2026 |
| Profit Margin | 35.27% |
| Operating Margin (TTM) | 26.29% |
| Diluted EPS (TTM) | 1.70 |
| Quarterly Revenue Growth (YOY) | 18.60% |
| Quarterly Earnings Growth (YOY) | 1.60% |
| Total Debt/Equity (MRQ) | 2.70% |
| Current Ratio (MRQ) | 5.34 |
| Operating Cash Flow (TTM) | 1.19 B |
| Levered Free Cash Flow (TTM) | 1.01 B |
| Return on Assets (TTM) | 11.54% |
| Return on Equity (TTM) | 22.80% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Genmab A/S | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | -1.0 |
| Technical Moving Averages | 3.5 |
| Technical Oscillators | -0.5 |
| Average | 1.25 |
|
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab’s proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab’s leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Large Growth |
| % Held by Institutions | 10.31% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Brandywine Global Investment Management, Llc | 31 Dec 2025 | 1,031,464 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 41.50 (Jefferies, 60.73%) | Buy |
| Median | 40.00 (54.92%) | |
| Low | 34.00 (Morgan Stanley, 31.68%) | Hold |
| Average | 39.10 (51.43%) | |
| Total | 4 Buy, 1 Hold | |
| Avg. Price @ Call | 29.62 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Wells Fargo | 02 Mar 2026 | 40.00 (54.92%) | Buy | 29.65 |
| Guggenheim | 23 Feb 2026 | 40.00 (54.92%) | Buy | 29.27 |
| HC Wainwright & Co. | 18 Feb 2026 | 40.00 (54.92%) | Buy | 29.16 |
| 28 Jan 2026 | 39.00 (51.05%) | Buy | 32.93 | |
| Jefferies | 17 Feb 2026 | 41.50 (60.73%) | Buy | 30.00 |
| Morgan Stanley | 16 Feb 2026 | 34.00 (31.68%) | Hold | 30.03 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |